NAD+ Nasal Spray vs Injection: Which Delivery Method Works Better?

Two Home NAD+ Delivery Methods: Nasal Spray vs Injection

Tmates GLP-1 program's injectable NAD+ program ($149/mo) offers both subcutaneous injection (1000mg/5ml, 200mg/ml) and nasal spray (300mg/ml) delivery options. Understanding the pharmacological differences helps patients and physicians choose the most appropriate method.

Subcutaneous injection delivers 1000mg of NAD+ into subcutaneous tissue with direct absorption into the bloodstream. Bioavailability is high — the NAD+ is absorbed directly without gut degradation, conversion steps, or the variable absorption of mucosal delivery. Onset is gradual over 1–2 hours as the subcutaneous depot is absorbed. Most clinical evidence for at-home NAD+ delivery is with subcutaneous injection, making it the reference method against which alternatives are compared.

Nasal spray (intranasal)** delivers NAD+ (300mg/ml) through the nasal mucosa, which has good vascular supply and allows direct absorption into circulation without first-pass hepatic metabolism. The nasal route has higher bioavailability than oral delivery and avoids the injection discomfort for patients who find self-injection difficult. Onset may be faster than subcutaneous (mucosal absorption can begin within minutes), but the total deliverable dose per administration is lower due to nasal cavity volume limitations. The 300mg/ml concentration and typical intranasal volume means each administration delivers a smaller NAD+ dose than the 1000mg injectable vial.